Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.

Jacobson CA, Sun L, Kim HT, McDonough SM, Reynolds CG, Schowalter M, Koreth J, Cutler CS, Ho VT, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Ritz J, Sarantopoulos S.

Biol Blood Marrow Transplant. 2014 May;20(5):668-75. doi: 10.1016/j.bbmt.2014.01.021. Epub 2014 Jan 23.

2.

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.

Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, Ho VT, Alyea EP, Koreth J, Blazar BR, Soiffer RJ, Antin JH, Ritz J.

Blood. 2009 Apr 16;113(16):3865-74. doi: 10.1182/blood-2008-09-177840. Epub 2009 Jan 23.

3.

B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.

Allen JL, Fore MS, Wooten J, Roehrs PA, Bhuiya NS, Hoffert T, Sharf A, Deal AM, Armistead P, Coghill J, Gabriel DA, Irons R, Essenmacher A, Shea TC, Richards K, Cutler C, Ritz J, Serody J, Baldwin AS, Sarantopoulos S.

Blood. 2012 Sep 20;120(12):2529-36. Epub 2012 Aug 14.

4.

Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.

Sarantopoulos S, Stevenson KE, Kim HT, Washel WS, Bhuiya NS, Cutler CS, Alyea EP, Ho VT, Soiffer RJ, Antin JH, Ritz J.

Blood. 2011 Feb 17;117(7):2275-83. doi: 10.1182/blood-2010-10-307819. Epub 2010 Nov 19.

5.

Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development.

Fedoriw Y, Samulski TD, Deal AM, Dunphy CH, Sharf A, Shea TC, Serody JS, Sarantopoulos S.

Biol Blood Marrow Transplant. 2012 Jun;18(6):968-73. doi: 10.1016/j.bbmt.2012.03.005. Epub 2012 Mar 20.

6.

High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.

Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ, Antin JH, Ritz J.

Clin Cancer Res. 2007 Oct 15;13(20):6107-14.

7.

B cells in chronic graft-versus-host disease.

Sarantopoulos S, Blazar BR, Cutler C, Ritz J.

Biol Blood Marrow Transplant. 2015 Jan;21(1):16-23. doi: 10.1016/j.bbmt.2014.10.029. Epub 2014 Nov 12. Review.

8.

Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.

Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1727-33. doi: 10.1016/j.bbmt.2012.06.014. Epub 2012 Jul 2.

9.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2013 Jun;19(6):934-9. doi: 10.1016/j.bbmt.2013.03.009. Epub 2013 Mar 21.

10.

CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome.

Kuzmina Z, Krenn K, Petkov V, Körmöczi U, Weigl R, Rottal A, Kalhs P, Mitterbauer M, Ponhold L, Dekan G, Greinix HT, Pickl WF.

Blood. 2013 Mar 7;121(10):1886-95. doi: 10.1182/blood-2012-06-435008. Epub 2013 Jan 9.

12.

Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.

Yeh AC, Brunner AM, Spitzer TR, Chen YB, Coughlin E, McAfee S, Ballen K, Attar E, Caron M, Preffer FI, Yeap BY, Dey BR.

Biol Blood Marrow Transplant. 2014 May;20(5):730-4. doi: 10.1016/j.bbmt.2014.02.003. Epub 2014 Feb 12.

13.

Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.

Moon JH, Sohn SK, Lambie A, Ellis L, Hamad N, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, Kim D.

Biol Blood Marrow Transplant. 2014 Apr;20(4):556-63. doi: 10.1016/j.bbmt.2014.01.010. Epub 2014 Jan 18.

14.

No impact of total or myeloid Cd34+ cell numbers on neutrophil engraftment and transplantation-related mortality after allogeneic pediatric bone marrow transplantation.

Pichler H, Witt V, Winter E, Boztug H, Glogova E, Pötschger U, Matthes-Martin S, Fritsch G.

Biol Blood Marrow Transplant. 2014 May;20(5):676-83. doi: 10.1016/j.bbmt.2014.01.026. Epub 2014 Jan 31.

15.

Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.

Bar M, Sandmaier BM, Inamoto Y, Bruno B, Hari P, Chauncey T, Martin PJ, Storb R, Maloney DG, Storer B, Flowers ME.

Biol Blood Marrow Transplant. 2013 Jun;19(6):949-57. doi: 10.1016/j.bbmt.2013.03.001. Epub 2013 Mar 21.

16.

High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation.

Cho BS, Min CK, Kim HJ, Lee S, Kim YJ, Lim JY, Jeong DC, Cho B, Kim HK, Eom KS, Cho SG, Kim DW, Lee JW, Min WS, Kim CC, Chung NG.

Biol Blood Marrow Transplant. 2010 May;16(5):629-38. doi: 10.1016/j.bbmt.2009.11.023. Epub 2009 Dec 4.

17.

Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.

Choi I, Yoon SR, Park SY, Kim H, Jung SJ, Jang YJ, Kang M, Yeom YI, Lee JL, Kim DY, Lee YS, Kang YA, Jeon M, Seol M, Lee JH, Lee JH, Kim HJ, Yun SC, Lee KH.

Biol Blood Marrow Transplant. 2014 May;20(5):696-704. doi: 10.1016/j.bbmt.2014.01.031. Epub 2014 Feb 11.

18.

Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.

Devillier R, Fürst S, El-Cheikh J, Castagna L, Harbi S, Granata A, Crocchiolo R, Oudin C, Mohty B, Bouabdallah R, Chabannon C, Stoppa AM, Charbonnier A, Broussais-Guillaumot F, Calmels B, Lemarie C, Rey J, Vey N, Blaise D.

Biol Blood Marrow Transplant. 2014 Mar;20(3):370-4. doi: 10.1016/j.bbmt.2013.11.030. Epub 2013 Dec 4.

19.

CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease.

Greinix HT, Kuzmina Z, Weigl R, Körmoczi U, Rottal A, Wolff D, Kralj M, Kalhs P, Mitterbauer M, Rabitsch W, Edinger M, Holler E, Pickl WF.

Biol Blood Marrow Transplant. 2015 Feb;21(2):250-8. doi: 10.1016/j.bbmt.2014.11.010. Epub 2014 Nov 20.

20.

Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.

Kim HT, Armand P, Frederick D, Andler E, Cutler C, Koreth J, Alyea EP 3rd, Antin JH, Soiffer RJ, Ritz J, Ho VT.

Biol Blood Marrow Transplant. 2015 May;21(5):873-80. doi: 10.1016/j.bbmt.2015.01.019. Epub 2015 Jan 23.

PMID:
25623931
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk